NR1H4 and diabetic kidney disease: However, given the differences between animals and humans, the design of FXR/TGR5 receptors for use in the clinic is still risky, and more clinical studies are needed to develop safer bile acid receptors in the future; these receptors will provide potential novel directions for the treatment of DKD.